Literature DB >> 20383511

Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy.

Joong Kyong Ahn, Jaejoon Lee, Hoon-Suk Cha, Eun-Mi Koh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20383511     DOI： 10.1007/s00296-010-1477-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  9 in total

1.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.

Authors:  Brett A Lenart; Dean G Lorich; Joseph M Lane
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

Review 2.  Treatment of osteoporosis: all the questions we still cannot answer.

Authors:  Michel Laroche
Journal:  Am J Med       Date:  2008-09       Impact factor: 4.965

3.  Severely suppressed bone turnover: a potential complication of alendronate therapy.

Authors:  Clarita V Odvina; Joseph E Zerwekh; D Sudhaker Rao; Naim Maalouf; Frank A Gottschalk; Charles Y C Pak
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

4.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

5.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

Review 6.  Emerging issues with bisphosphonates.

Authors:  Ian R Reid
Journal:  Rheum Dis Clin North Am       Date:  2006-11       Impact factor: 2.670

7.  Severely suppressed bone turnover and atypical skeletal fragility.

Authors:  Maja Visekruna; Deborah Wilson; Fergus Eoin McKiernan
Journal:  J Clin Endocrinol Metab       Date:  2008-06-03       Impact factor: 5.958

8.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Authors:  Ernest Beng Kee Kwek; Seo Kiat Goh; Joyce Suang Bee Koh; Meng Ai Png; Tet Sen Howe
Journal:  Injury       Date:  2008-01-28       Impact factor: 2.586

9.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741
  9 in total
  2 in total

1.  Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Authors:  Mark L Prasarn; Jaimo Ahn; David L Helfet; Joseph M Lane; Dean G Lorich
Journal:  Clin Orthop Relat Res       Date:  2012-06-06       Impact factor: 4.176

2.  Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Authors:  Joseph D Isaacs; Louis Shidiak; Ian A Harris; Zoltan L Szomor
Journal:  Clin Orthop Relat Res       Date:  2010-08-31       Impact factor: 4.176
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.